BioSpace News Archive

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes.

Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1.

CorMedix Inc. today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

Nanomix Corporation today announced a new distribution agreement with Diaclinic SpA (“Diaclinic”), a medical distributor headquartered in Santiago, Chile.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022.

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced additional changes in its Board of Directors (the “Board”).

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,471,406 to IntelGenx.

Day Zero Diagnostics Inc. today announced it was awarded $8.2 million in additional option stage funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership dedicated to accelerating early antibacterial research and development to address the rising global threat of drug-resistant bacteria.

LEO Pharma Announces European Commission Approval of Adtralza ® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents.

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.